Lyudmila Bazhenova
柳德米拉·巴热诺娃
MD
Professor of Medicine, Thoracic Medical Oncology医学教授，胸部肿瘤内科
👥Biography 个人简介
Dr. Lyudmila Bazhenova is a UCSD thoracic oncologist specializing in SCLC and rare lung malignancies. She led pivotal studies of tarlatamab (DLL3xCD3 BiTE), contributing to its FDA approval for relapsed SCLC, and investigates novel immunotherapy approaches for difficult-to-treat thoracic cancers.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Tarlatamab & SCLC Immunotherapy
Instrumental in the DeLLphi-301 trial of tarlatamab for relapsed SCLC, supporting FDA approval of this first-in-class DLL3-targeting BiTE antibody and pioneering immunotherapy for rare thoracic tumors.
Representative Works 代表性著作
Tarlatamab for Small-Cell Lung Cancer after at Least Two Lines of Prior Therapy (DeLLphi-301)
New England Journal of Medicine (2023)
Phase II study demonstrating durable responses with tarlatamab in relapsed SCLC, leading to FDA approval in 2024.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 柳德米拉·巴热诺娃 的研究动态
Follow Lyudmila Bazhenova's research updates
留下邮箱，当我们发布与 Lyudmila Bazhenova（UC San Diego Moores Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment